What dosing regimen of carfilzomib do you use in the front line setting for high risk transplant-eligible multiple myeloma?
Answer from: Medical Oncologist at Academic Institution
I almost never use carfilzomib in the front line setting, as there is almost no evidence to support its use over bortezomib in this setting.
When I do give carfilzomib in combination with lenalidomide, I generally extrapolate from the twice weekly 36 mg/m2 dosing and combine those into a single wee...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
20/36 dosing with KRd for NDMM with pre-existing PN or suboptimal response to 4 cycles of bortezomib based induction (less than PR)
Answer from: Medical Oncologist at Academic Institution
weekly 20/56 along with lenalidomide based on ASCO 2018 abstract 8022